212 related articles for article (PubMed ID: 29752261)
21. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the Expression of Surface Receptors on NK Cells and NKG2D on Immunocytes in Peripheral Blood of Patients with Nasopharyngeal Carcinoma.
Xu Y; Zhou R; Huang C; Zhang M; Li J; Zong J; Qiu S; Lin S; Chen H; Ye Y; Pan J
Asian Pac J Cancer Prev; 2018 Mar; 19(3):661-665. PubMed ID: 29580037
[TBL] [Abstract][Full Text] [Related]
24. Enhanced activation of human NK cells by drug-exposed hepatocytes.
Fasbender F; Obholzer M; Metzler S; Stöber R; Hengstler JG; Watzl C
Arch Toxicol; 2020 Feb; 94(2):439-448. PubMed ID: 32060585
[TBL] [Abstract][Full Text] [Related]
25. CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival.
Ullrich N; Heinemann A; Nilewski E; Scheffrahn I; Klode J; Scherag A; Schadendorf D; Singer BB; Helfrich I
Cancer Res; 2015 May; 75(9):1897-907. PubMed ID: 25744717
[TBL] [Abstract][Full Text] [Related]
26. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity.
Ghio M; Contini P; Negrini S; Boero S; Musso A; Poggi A
Eur J Immunol; 2009 Dec; 39(12):3459-68. PubMed ID: 19830740
[TBL] [Abstract][Full Text] [Related]
27. NKG2D and natural cytotoxicity receptors are involved in natural killer cell interaction with self-antigen presenting cells and stromal cells.
Poggi A; Prevosto C; Zancolli M; Canevali P; Musso A; Zocchi MR
Ann N Y Acad Sci; 2007 Aug; 1109():47-57. PubMed ID: 17785290
[TBL] [Abstract][Full Text] [Related]
28. Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients.
Mirjačić Martinović KM; Babović NLj; Džodić RR; Jurišić VB; Tanić NT; Konjević GM
Melanoma Res; 2014 Aug; 24(4):295-304. PubMed ID: 24769842
[TBL] [Abstract][Full Text] [Related]
29. Innate immunity protein Tag7 (PGRP-S) activates lymphocytes capable of Fasl-Fas-dependent contact killing of virus-infected cells.
Sharapova TN; Ivanova OK; Prasolov VS; Romanova EA; Sashchenko LP; Yashin DV
IUBMB Life; 2017 Dec; 69(12):971-977. PubMed ID: 29083508
[TBL] [Abstract][Full Text] [Related]
30. In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-α alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression.
Konjevic G; Mirjacic-Martinovic K; Vuletic A; Babovic N
J BUON; 2012; 17(4):761-9. PubMed ID: 23335538
[TBL] [Abstract][Full Text] [Related]
31. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors.
Poggi A; Prevosto C; Massaro AM; Negrini S; Urbani S; Pierri I; Saccardi R; Gobbi M; Zocchi MR
J Immunol; 2005 Nov; 175(10):6352-60. PubMed ID: 16272287
[TBL] [Abstract][Full Text] [Related]
32. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis.
Ma D; Niederkorn JY
Immunology; 1995 Oct; 86(2):263-9. PubMed ID: 7490128
[TBL] [Abstract][Full Text] [Related]
33. Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack.
Wang W; Guo H; Geng J; Zheng X; Wei H; Sun R; Tian Z
J Biol Chem; 2014 Nov; 289(48):33311-9. PubMed ID: 25315772
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines.
Noguchi K; Dalton AC; Howley BV; McCall BJ; Yoshida A; Diehl JA; Howe PH
PLoS One; 2017; 12(5):e0177830. PubMed ID: 28545079
[TBL] [Abstract][Full Text] [Related]
35. Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control.
Grassi ML; Palma CS; Thomé CH; Lanfredi GP; Poersch A; Faça VM
J Proteomics; 2017 Jan; 151():2-11. PubMed ID: 27394697
[TBL] [Abstract][Full Text] [Related]
36. The natural killer cell response to West Nile virus in young and old individuals with or without a prior history of infection.
Yao Y; Strauss-Albee DM; Zhou JQ; Malawista A; Garcia MN; Murray KO; Blish CA; Montgomery RR
PLoS One; 2017; 12(2):e0172625. PubMed ID: 28235099
[TBL] [Abstract][Full Text] [Related]
37. MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal.
Menier C; Riteau B; Carosella ED; Rouas-Freiss N
Int J Cancer; 2002 Jul; 100(1):63-70. PubMed ID: 12115588
[TBL] [Abstract][Full Text] [Related]
38. Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21.
Jiang B; Wu X; Li XN; Yang X; Zhou Y; Yan H; Wei AH; Yan W
Cell Immunol; 2014 Jul; 290(1):10-20. PubMed ID: 24859012
[TBL] [Abstract][Full Text] [Related]
39. Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor.
López-Soto A; Huergo-Zapico L; Galván JA; Rodrigo L; de Herreros AG; Astudillo A; Gonzalez S
J Immunol; 2013 Apr; 190(8):4408-19. PubMed ID: 23509364
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
